<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml"><head><title>R: pancreatic2</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link rel="stylesheet" type="text/css" href="R.css" />
</head><body><div class="container">

<table width="100%" summary="page for pancreatic2"><tr><td>pancreatic2</td><td style="text-align: right;">R Documentation</td></tr></table>

<h2>pancreatic2

</h2>

<h3>Description</h3>

<p>This is the same data as in 'pancreatic', with overall and progression-free survival calculated. Dates have been removed.
</p>


<h3>Usage</h3>

<pre>data("pancreatic2")</pre>


<h3>Format</h3>

<p>A data frame with 41 observations on the following 4 variables.
</p>

<dl>
<dt><code>pfs</code></dt><dd><p>Progression-free survival: Time from entry until disease progression. 
If no progression was observed, before death, the time to death is used.</p>
</dd>
<dt><code>os</code></dt><dd><p>Overall survival: Time from entry until death</p>
</dd>
<dt><code>status</code></dt><dd><p>This censoring indicator is 1 for all patients, since all patients died.</p>
</dd>
<dt><code>stage</code></dt><dd><p>a factor with levels <code>LA</code> (locally advanced) or <code>M</code> (metastatic)</p>
</dd>
</dl>



<h3>References</h3>

<p>Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012)
A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointestinal Cancer Research 5, 77 - 83.
</p>


<h3>Examples</h3>

<pre>
data(pancreatic2)

</pre>


</div></body></html>
